Analogous detection of circulating tumor cells using the AccuCyte®-CyteFinder® system and ISET system in patients with locally advanced and metastatic prostate cancer

Emma E. van der Toom, Vincent P. Groot, Stephanie A. Glavaris, Georgios Gemenetzis, Heather J. Chalfin, Laura Delong Wood, Christopher Wolfgang, Jean J.M.C.H. de la Rosette, Theo M. de Reijke, Kenneth Pienta

Research output: Contribution to journalArticle

Abstract

Introduction: Circulating tumor cells (CTCs) can provide important information on patient's prognosis and treatment efficacy. Currently, a plethora of methods is available for the detection of these rare cells. We compared the outcomes of two of those methods to enumerate and characterize CTCs in patients with locally advanced and metastatic prostate cancer (PCa). First, the selection-free AccuCyte® - CyteFinder® system (RareCyte®, Inc., Seattle, WA) and second, the ISET system (Rarecells Diagnostics, France), a CTC detection method based on cell size-exclusion. Methods: Peripheral blood samples were obtained from 15 patients with metastatic PCa and processed in parallel, using both methods according to manufacturer's protocol. CTCs were identified by immunofluorescence, using commercially available antibodies to pancytokeratin (PanCK), EpCAM, CD45/CD66b/CD34/CD11b/CD14 (AccuCyte® - CyteFinder® system), and pancytokeratin, vimentin (Vim) and CD45 (ISET system). Results: The median CTC count was 5 CTCs/7.5mL (range, 0-20) for the AccuCyte® - CyteFinder® system and 37 CTCs/7.5mL (range, 8-139) for the ISET system (P<0.001). Total CTC counts obtained for the two methods were correlated (r=0.750, P=0.001). When separating the total CTC count obtained with the ISET system in PanCK+/Vim- and PanCK+/Vim+ CTCs, the total CTC count obtained with the AccuCyte® - CyteFinder® system was moderately correlated with the PanCK+/Vim- CTCs, and strongly correlated with the PanCK+/Vim+ CTCs (r=0.700, P=0.004 and r=0.810, P<0.001, respectively). Conclusion: Our results highlight significant disparities in the enumeration and phenotype of CTCs detected by both techniques. Although the median amount of CTCs/7.5mL differed significantly, total CTC counts of both methods were strongly correlated. For future studies, a more uniform approach to the isolation and definition of CTCs based on immunofluorescent stains is needed to provide reproducible results that can be correlated with clinical outcomes.

Original languageEnglish (US)
JournalProstate
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Circulating Neoplastic Cells
Prostatic Neoplasms
Vimentin
Cell Count

Keywords

  • AccuCyte - CyteFinder system
  • Circulating tumor cells
  • CTCs
  • ISET system
  • Metastatic prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Analogous detection of circulating tumor cells using the AccuCyte®-CyteFinder® system and ISET system in patients with locally advanced and metastatic prostate cancer. / van der Toom, Emma E.; Groot, Vincent P.; Glavaris, Stephanie A.; Gemenetzis, Georgios; Chalfin, Heather J.; Wood, Laura Delong; Wolfgang, Christopher; de la Rosette, Jean J.M.C.H.; de Reijke, Theo M.; Pienta, Kenneth.

In: Prostate, 01.01.2018.

Research output: Contribution to journalArticle

van der Toom, Emma E. ; Groot, Vincent P. ; Glavaris, Stephanie A. ; Gemenetzis, Georgios ; Chalfin, Heather J. ; Wood, Laura Delong ; Wolfgang, Christopher ; de la Rosette, Jean J.M.C.H. ; de Reijke, Theo M. ; Pienta, Kenneth. / Analogous detection of circulating tumor cells using the AccuCyte®-CyteFinder® system and ISET system in patients with locally advanced and metastatic prostate cancer. In: Prostate. 2018.
@article{35173a9b27444f2cb39be2149658f51f,
title = "Analogous detection of circulating tumor cells using the AccuCyte{\circledR}-CyteFinder{\circledR} system and ISET system in patients with locally advanced and metastatic prostate cancer",
abstract = "Introduction: Circulating tumor cells (CTCs) can provide important information on patient's prognosis and treatment efficacy. Currently, a plethora of methods is available for the detection of these rare cells. We compared the outcomes of two of those methods to enumerate and characterize CTCs in patients with locally advanced and metastatic prostate cancer (PCa). First, the selection-free AccuCyte{\circledR} - CyteFinder{\circledR} system (RareCyte{\circledR}, Inc., Seattle, WA) and second, the ISET system (Rarecells Diagnostics, France), a CTC detection method based on cell size-exclusion. Methods: Peripheral blood samples were obtained from 15 patients with metastatic PCa and processed in parallel, using both methods according to manufacturer's protocol. CTCs were identified by immunofluorescence, using commercially available antibodies to pancytokeratin (PanCK), EpCAM, CD45/CD66b/CD34/CD11b/CD14 (AccuCyte{\circledR} - CyteFinder{\circledR} system), and pancytokeratin, vimentin (Vim) and CD45 (ISET system). Results: The median CTC count was 5 CTCs/7.5mL (range, 0-20) for the AccuCyte{\circledR} - CyteFinder{\circledR} system and 37 CTCs/7.5mL (range, 8-139) for the ISET system (P<0.001). Total CTC counts obtained for the two methods were correlated (r=0.750, P=0.001). When separating the total CTC count obtained with the ISET system in PanCK+/Vim- and PanCK+/Vim+ CTCs, the total CTC count obtained with the AccuCyte{\circledR} - CyteFinder{\circledR} system was moderately correlated with the PanCK+/Vim- CTCs, and strongly correlated with the PanCK+/Vim+ CTCs (r=0.700, P=0.004 and r=0.810, P<0.001, respectively). Conclusion: Our results highlight significant disparities in the enumeration and phenotype of CTCs detected by both techniques. Although the median amount of CTCs/7.5mL differed significantly, total CTC counts of both methods were strongly correlated. For future studies, a more uniform approach to the isolation and definition of CTCs based on immunofluorescent stains is needed to provide reproducible results that can be correlated with clinical outcomes.",
keywords = "AccuCyte - CyteFinder system, Circulating tumor cells, CTCs, ISET system, Metastatic prostate cancer",
author = "{van der Toom}, {Emma E.} and Groot, {Vincent P.} and Glavaris, {Stephanie A.} and Georgios Gemenetzis and Chalfin, {Heather J.} and Wood, {Laura Delong} and Christopher Wolfgang and {de la Rosette}, {Jean J.M.C.H.} and {de Reijke}, {Theo M.} and Kenneth Pienta",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/pros.23474",
language = "English (US)",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - Analogous detection of circulating tumor cells using the AccuCyte®-CyteFinder® system and ISET system in patients with locally advanced and metastatic prostate cancer

AU - van der Toom, Emma E.

AU - Groot, Vincent P.

AU - Glavaris, Stephanie A.

AU - Gemenetzis, Georgios

AU - Chalfin, Heather J.

AU - Wood, Laura Delong

AU - Wolfgang, Christopher

AU - de la Rosette, Jean J.M.C.H.

AU - de Reijke, Theo M.

AU - Pienta, Kenneth

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Introduction: Circulating tumor cells (CTCs) can provide important information on patient's prognosis and treatment efficacy. Currently, a plethora of methods is available for the detection of these rare cells. We compared the outcomes of two of those methods to enumerate and characterize CTCs in patients with locally advanced and metastatic prostate cancer (PCa). First, the selection-free AccuCyte® - CyteFinder® system (RareCyte®, Inc., Seattle, WA) and second, the ISET system (Rarecells Diagnostics, France), a CTC detection method based on cell size-exclusion. Methods: Peripheral blood samples were obtained from 15 patients with metastatic PCa and processed in parallel, using both methods according to manufacturer's protocol. CTCs were identified by immunofluorescence, using commercially available antibodies to pancytokeratin (PanCK), EpCAM, CD45/CD66b/CD34/CD11b/CD14 (AccuCyte® - CyteFinder® system), and pancytokeratin, vimentin (Vim) and CD45 (ISET system). Results: The median CTC count was 5 CTCs/7.5mL (range, 0-20) for the AccuCyte® - CyteFinder® system and 37 CTCs/7.5mL (range, 8-139) for the ISET system (P<0.001). Total CTC counts obtained for the two methods were correlated (r=0.750, P=0.001). When separating the total CTC count obtained with the ISET system in PanCK+/Vim- and PanCK+/Vim+ CTCs, the total CTC count obtained with the AccuCyte® - CyteFinder® system was moderately correlated with the PanCK+/Vim- CTCs, and strongly correlated with the PanCK+/Vim+ CTCs (r=0.700, P=0.004 and r=0.810, P<0.001, respectively). Conclusion: Our results highlight significant disparities in the enumeration and phenotype of CTCs detected by both techniques. Although the median amount of CTCs/7.5mL differed significantly, total CTC counts of both methods were strongly correlated. For future studies, a more uniform approach to the isolation and definition of CTCs based on immunofluorescent stains is needed to provide reproducible results that can be correlated with clinical outcomes.

AB - Introduction: Circulating tumor cells (CTCs) can provide important information on patient's prognosis and treatment efficacy. Currently, a plethora of methods is available for the detection of these rare cells. We compared the outcomes of two of those methods to enumerate and characterize CTCs in patients with locally advanced and metastatic prostate cancer (PCa). First, the selection-free AccuCyte® - CyteFinder® system (RareCyte®, Inc., Seattle, WA) and second, the ISET system (Rarecells Diagnostics, France), a CTC detection method based on cell size-exclusion. Methods: Peripheral blood samples were obtained from 15 patients with metastatic PCa and processed in parallel, using both methods according to manufacturer's protocol. CTCs were identified by immunofluorescence, using commercially available antibodies to pancytokeratin (PanCK), EpCAM, CD45/CD66b/CD34/CD11b/CD14 (AccuCyte® - CyteFinder® system), and pancytokeratin, vimentin (Vim) and CD45 (ISET system). Results: The median CTC count was 5 CTCs/7.5mL (range, 0-20) for the AccuCyte® - CyteFinder® system and 37 CTCs/7.5mL (range, 8-139) for the ISET system (P<0.001). Total CTC counts obtained for the two methods were correlated (r=0.750, P=0.001). When separating the total CTC count obtained with the ISET system in PanCK+/Vim- and PanCK+/Vim+ CTCs, the total CTC count obtained with the AccuCyte® - CyteFinder® system was moderately correlated with the PanCK+/Vim- CTCs, and strongly correlated with the PanCK+/Vim+ CTCs (r=0.700, P=0.004 and r=0.810, P<0.001, respectively). Conclusion: Our results highlight significant disparities in the enumeration and phenotype of CTCs detected by both techniques. Although the median amount of CTCs/7.5mL differed significantly, total CTC counts of both methods were strongly correlated. For future studies, a more uniform approach to the isolation and definition of CTCs based on immunofluorescent stains is needed to provide reproducible results that can be correlated with clinical outcomes.

KW - AccuCyte - CyteFinder system

KW - Circulating tumor cells

KW - CTCs

KW - ISET system

KW - Metastatic prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85039546099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039546099&partnerID=8YFLogxK

U2 - 10.1002/pros.23474

DO - 10.1002/pros.23474

M3 - Article

JO - Prostate

JF - Prostate

SN - 0270-4137

ER -